Hep C

AbbVie’s 8-week hepatitis C drug granted early access in UK

https://pharmaphorum.com/news/abbvies-hepatitis-c-drug-granted-early-access-uk/

The future of healthcare: the patient advocate and investor perspectives

https://pharmaphorum.com/views-and-analysis/future-healthcare-patient-advocate-investor-perspectives/

The biggest pharma stories of 2016 so far

https://pharmaphorum.com/views-and-analysis/biggest-pharma-stories-2016-far/

After 2015’s ‘breakthrough’ year for pharma approvals, will 2016 see a dip?

https://pharmaphorum.com/views-and-analysis/2015-breakthrough-year-pharma-approvals-will-2016-see-dip/

Many millions still untreated – but hep C boom is already over

https://pharmaphorum.com/views-and-analysis/many-millions-left-untreated-hepatitis-c-boom-already/

Move to eradicate viral hepatitis

https://pharmaphorum.com/views-and-analysis/move-eradicate-viral-hepatitis/

We can eradicate Hepatitis C in the emerging world – here’s how

https://pharmaphorum.com/views-and-analysis/eradicate-hepatitis-c-in-the-emerging-world/

AbbVie’s hep C combination approved in Europe

https://pharmaphorum.com/news/abbvies-hep-c-combination-approved-in-europe/

Close in 10 seconds

Pharmaphorum.com

Search